Low oxygen tension (hypoxia) is a hallmark of cancer that influences cancer cell function, but is also an important component of the tumour microenvironment as it alters the extracellular matrix, modulates the tumour immune response and increases angiogenesis. Here we discuss the regulation and role of hypoxia and its key transcriptional mediators, the hypoxia-inducible factor (HIF) family of transcription factors, in the tumour microenvironment and stromal compartments.
1
. Hypoxia arises due to a combination of excessive oxygen consumption by cells in the tumour, and the leaky and disorganized tumour-associated vasculature, which leads to both acute fluxes in oxygen tension and diffusion-limited regions of low oxygen levels within the tumour 2 . Tumour hypoxia is associated with increased genetic instability, disease progression and metastasis, and can inhibit tumour response to cytotoxic and targeted therapies 1 . Its profound clinical implications have led to an intensive effort to characterize the cellular response to hypoxia, and to modulate it for therapeutic benefit.
Tumours are composed of a heterogeneous mix of malignant and stromal cell populations, the latter including cancer-associated fibroblasts, immune cells, endothelial cells and pericytes 3 . Stromal cells are intimately associated with malignant cells and participate in paracrine signalling, metabolite exchange, extracellular matrix remodelling and regulation of immune surveillance in the tumour 3 . Microenvironmental cues, including hypoxia, synergistically modulate the behaviour of tumour cells and associated stromal cells to potentiate tumour progression 4 . Central in the cellular responses of both the tumour and stromal compartments to hypoxia is the hypoxia-inducible factor (HIF) family of transcription factors. In this Review, we discuss the regulation of HIF signalling and the role of the hypoxic microenvironment in shaping the tumour-stromal cell interface.
Canonical regulation of HIF signalling HIF-1α, HIF-2α and the lesser-studied HIF-3α constitute a family of oxygen-sensitive basic helix-loop-helix transcription factors that direct the transcriptional response to hypoxia 5 . HIF-1α is ubiquitously expressed in human cells, whereas HIF-2α expression is restricted to specific tissues and cell types 6 . Transcriptional activation of HIF target genes requires assembly of a heterodimer between HIF-1α or HIF-2α and their obligate binding partner, the aryl hydrocarbon nuclear translocator (ARNT, also known as HIF-1β) 7 . Under normoxic conditions, α-ketoglutarate-dependent prolyl hydroxylases (PHDs) catalyse the hydroxylation of proline residues within oxygen-dependent degradation domains of HIF-α, which are recognized by the Von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, leading to HIF-α ubiquitination and subsequent degradation 8, 9 ( Fig. 1a) . Owing to its crucial role in HIF-α degradation, loss-of-function mutations in the VHL gene result in constitutive activation of HIF signalling and are characteristic of several cancer types, including clear cell renal cell carcinoma (ccRCC) 10 . In addition to regulation by prolyl hydroxylation, oxygen-dependent hydroxylation of a key asparagine residue by factor-inhibiting HIF (FIH) disrupts binding of the p300 transcriptional coactivator to HIF, thereby inhibiting its transcriptional activation potential 11 . Oxygendependent hydroxylases provide an elegant oxygen-sensing mechanism that directs the transcriptional response to hypoxia.
Non-canonical regulation of HIF signalling
In addition to the canonical oxygen-dependent regulation of HIF-α, non-canonical regulation of HIF signalling has been demonstrated in many cell types, including both malignant and stromal cells. Activation of PI(3)K-mTOR signalling increases cap-dependent translation of HIF-α mRNA, resulting in increased expression of HIF-α protein [12] [13] [14] ( Fig. 1b) . In cancer cells, frequent activation of the PI(3)K-mTOR axis stimulates HIF-α activity and promotes tumour angiogenesis 15, 16 . In Peutz-Jeghers syndrome, dysregulation of mTOR signalling downstream of LKB1 (liver kinase B1) loss leads to metabolic reprogramming by a HIF-dependent mechanism 17, 18 . The RNA-and DNA-binding protein YB-1, which is upregulated in sarcomas, can also regulate cap-dependent translation of HIF-1α, but not HIF-2α, and has separately been reported to indirectly regulate HIF-1α by transcriptional repression of FOXO3a (Forkhead box O 3a) 19, 20 . Activation of mTOR signalling, and subsequent HIF-α stabilization and activation, also occurs downstream of T-cell receptor (TCR) signalling in T cells, and is imperative for their function, because it drives metabolic reprogramming and prolongs survival of peripheral T cells under hypoxia 21, 22 (Fig. 2a) . HIF-α signalling in lymphocytes is also modulated by pro-inflammatory cytokines such as IL-6 (interleukin-6), which signal through the JAK-STAT3 pathway to increase transcription of HIF-α mRNA 23, 24 . In the innate immune system, toll-like receptor (TLR) signalling induces HIF-α expression in myeloid cells through increased NF-κB (nuclear factor-κB)-dependent transcription of Hif1a mRNA, highlighting an important link between innate immunity and the HIF pathway [25] [26] [27] (Figs 1b and 2a) . These findings indicate that additional, oxygen-independent mechanisms in normal and malignant cells drive activation of HIF signalling, to sustain the function of these cell types.
Mitochondrial regulation of HIF activity
Reprogramming of cellular metabolism towards increased glycolysis and suppressed oxidative phosphorylation is a major adaptation mechanism to hypoxia. HIF-α transcription factors are central regulators of metabolism, and several HIF target genes encode metabolic enzymes. In turn, a wide range of cellular metabolites can modulate HIF signalling. Numerous reports indicate that mitochondria, the major site of cellular oxygen consumption, are important for HIF-α stabilization under both hypoxic and non-hypoxic conditions. One hypothesis is that mitochondrial respiration regulates HIF-α stability by increasing intracellular hypoxia, thereby impairing PHD-mediated HIF-α hydroxylation. Indeed, high-resolution imaging indicates that mitochondria reside in regions of lower oxygen compared with other cellular compartments 28 , and mitochondrial electron transport chain inhibitors interfere with hypoxic stabilization of HIF-α, presumably by preserving intracellular oxygen for PHD-mediated hydroxylation 29 . Furthermore, PGC-1α (peroxisome proliferator-activated receptor gamma, coactivator-1α), a central regulator of mitochondrial biogenesis, stabilizes HIF-α by stimulating mitochondrial oxygen consumption and increasing intracellular hypoxia 30, 31 . HIF was recently shown to repress PGC-1α expression in ccRCC, suggesting that a regulatory loop exists between HIF-α and PGC-1α, linking oxygen sensing to mitochondrial biogenesis 32 . Aberrant metabolism and oncogene activation frequently induces reactive oxygen species (ROS) accumulation, which both positively and negatively influences tumorigenesis 33 . In vitro models blocking mitochondrial ROS production indicate that ROS are an important mediator of HIF stability, acting by inhibiting PHD function [34] [35] [36] [37] . However, the tight coupling between ROS production and oxygen consumption in the mitochondria have made it difficult to discern whether mitochondria regulate HIF through consumption of oxygen or production of ROS. Whether ROS production in the mitochondria is increased or decreased under hypoxic conditions remains unclear and, adding to the controversial role of ROS as mediators of HIF signalling, recent reports indicate that the activity of FIH, but not the PHDs, is sensitive to peroxide radicals 38, 39 .
Influence of intracellular metabolites on HIF-α stability Loss-of-function mutations to genes encoding the succinate dehydrogenase complex and fumarate hydratase lead to accumulation of succinate or fumarate respectively, metabolites that inhibit the activity of the PHDs and result in HIF-α stabilization 40 ( Fig. 2b) . Other intracellular metabolites, including pyruvate, lactate and oxaloacetate, can also modulate HIF signalling through PHD inhibition 41 . Isocitrate dehydrogenase isoforms (most commonly IDH1 and IDH2) are also frequently mutated in multiple cancer types 42 . These mutations result in neomorphic IDH activity, with mutant IDH1/2 producing 2-hydroxyglutarate (2-HG) instead of α-ketoglutarate, which is an essential co-substrate of the PHDs 43 . The impact of 2-HG on HIF stability is hotly contested, with reports suggesting that 2-HG can either activate or inhibit PHD-mediated hydroxylation of HIF-α in an enantiomer-specific manner 44 . Further complicating matters, IDH3α expression has been reported to repress or activate HIF stability in CAFs and malignant cells by modulating intracellular α-ketoglutarate levels 45, 46 . How IDH3α can increase or decrease α-ketoglutarate levels to modulate HIF signalling in different contexts remains unclear.
HIF function can also be modulated by non-catalytic functions of metabolic enzymes. The gluconeogenic enzyme fructose-1,6-bisphosphatase (FBP1) binds to the inhibitory domain on HIF, thereby preventing HIF nuclear translocation and transactivating potential, and inhibiting ccRCC tumorigenesis 47 . In contrast, the PKM2 isoform of pyruvate kinase can act as a HIF-1α coactivator by recruiting p300 48 . Dimeric PKM2 can also activate Stat3, which is known to coordinate expression of genes involved in inflammation and the hypoxic response together with HIF-α, suggesting that PKM2 may act as a metabolic sensor integrating these two gene expression programs 49 . Together, these studies indicate that both metabolites and metabolic enzymes can directly modulate oxygen sensing.
Hypoxia and HIF signalling in the tumour microenvironment Tumour-associated stromal cells are exposed to similar, often harsh, microenvironmental cues as tumour cells. HIF signalling promotes adaptation to these microenvironmental conditions and, in doing so, induces changes in both tumour and stromal cells that potentiate tumorigenesis. Tumour hypoxia promotes the recruitment of endothelial cells and pericytes to stimulate angiogenesis and facilitates the recruitment of bone-marrow-derived cells. Recruited stromal cells enhance tumorigenesis through extracellular matrix remodelling, growth factor signalling and evasion of the anti-tumour immune response 3 ( Fig. 3 ). The hypoxic tumour microenvironment spurs adaptive metabolic changes that complement the metabolic flux of normoxic tumour regions to sustain metabolic fitness in both compartments in a process termed metabolic symbiosis. For example, the lactate secreted by highly glycolytic hypoxic cells is consumed by normoxic cells for ATP production via oxidative phosphorylation 50 ( Fig. 3 ). In addition to poor oxygenation, a consequence of the malformed tumour-associated vasculature is limiting nutrient supply. By-products of hypoxic cell metabolism may alter the function and viability of a wide range of stromal cells by increasing tissue acidity and by depriving stromal cells of access to essential nutrients 51 . Augmented HIF signalling and oncogene activation in tumour cells improves metabolic fitness, allowing tumour cells to outcompete stromal cells for vital metabolites such as glucose and glutamine 52 . This dynamic competition for nutrients between tumour cells and their stroma has recently been implicated in the exhaustion of tumour-infiltrating lymphocytes, and indicates that metabolic competition promotes immune suppression in the tumour microenvironment 53, 54 .
Vascular endothelial cells and pericytes
The contribution of angiogenesis to tumour progression is well established 55 . Although early in tumorigenesis the resident tissue vasculature supplies sufficient oxygen to the burgeoning tumour, larger tumours exhibit significant regions of hypoxia that limit further tumour growth. Hypoxic cancer and stromal cells secrete soluble factors, such as vascular endothelial growth factor (VEGF), that facilitate angiogenesis and thereby oxygen and nutrient delivery to promote tumour growth under hypoxic conditions. Two major vascular cell types are the endothelial cells that line blood vessels and the pericytes that surround blood vessels, and hypoxia and HIF signalling are known to influence both. . Endothelial cells respond to VEGF secretion from cancer and stromal cells by sprouting from the existing vasculature to form new vessels during angiogenesis. Sprouting vessels culminate in specialized vascular endothelial cells (tip cells) that direct vessel formation. As these tip cells reside far from functional vessels, they become hypoxic and must mount an adaptive response to hypoxia 57 . Thus, during vessel sprouting, endothelial cells exhibit unique patterns of cellular metabolism, with high rates of glycolysis and a dependence on fatty acid oxidation for nucleic acid synthesis and proliferation 58, 59 , despite the fact that hypoxia suppresses fatty acid oxidation in a wide range of cell types and tissues [60] [61] [62] [63] . These findings indicate that endothelial cells may exhibit unique metabolic behaviours that could be targeted therapeutically to block tumour angiogenesis.
Early evidence of the role of HIF signalling in endothelial cells came from studies in which conditional deletion of HIF-1α in endothelial cells impaired vascularization and tumour growth 64 . Surprisingly, deletion of endothelial HIF-2α enhanced tumour angiogenesis, but the resulting vasculature was highly disorganized and the resulting tumours were more hypoxic 65, 66 . Additionally, heterozygous loss of PHD2 (Egln1) resulted in increased HIF-α stabilization, normalized tumour vasculature, increased oxygenation and diminished metastasis 67 . These findings indicate that HIF signalling in endothelial cells plays an essential and complex role in functional angiogenesis.
Tumour-associated endothelial cells also represent an important barrier to intravasation of invading tumour cells. HIF-1α and HIF-2α play opposing roles in regulating the barrier function of endothelial cells: loss of endothelial HIF-1α impairs tumour cell migration through endothelial layers, whereas endothelial HIF-2α deficiency enhances tumour cell migration and metastasis 68 . These contradictory roles for HIF signalling in endothelial cells may be explained by diminished production of inducible nitric oxide synthase (iNOS) in HIF-1α-deficient endothelial cells, compared with enhanced iNOS production under HIF-2α deficiency; however, more work is needed to elucidate these contrasting roles of HIF-1α and HIF-2α.
Pericytes. Vascular endothelial cells are tightly associated with pericytes, which line the outside of blood vessels 69 . Pericytes are an important component of functional vasculature, contributing to vessel contractility and permeability to ensure efficient nutrient and oxygen delivery to healthy tissues. During angiogenesis, pericytes respond to platelet-derived growth factor (PDGF) to induce neovascularization. Whereas VEGF promotes endothelial cell proliferation and migration, PDGF disrupts pericyte coverage of nascent blood vessels, resulting in pericytes being more weakly attached to tumour-associated vasculature 70, 71 . Preclinical models of pericyte deficiency indicate that decreased pericyte vessel coverage drives increased hypoxia, tumour aggressiveness and metastasis 72, 73 . The role of pericytes in tumour biology may fluctuate at different stages of tumour progression: pericyte depletion at early stages of tumour growth can decrease growth and metastasis, whereas their depletion at later stages enhances intratumoural hypoxia and has the converse effect 72, 73 .
Hypoxia and anti-angiogenic therapy. A major focus of targeted cancer therapy has been the inhibition of angiogenesis through VEGF blockade 74 . Although these therapies often induce acute tumour shrinkage, increased hypoxia resulting from vessel pruning can promote tumour aggressiveness and metastatic dissemination 69 . Concomitant treatment with semaphorin 3A (Sema3A) during VEGF blockade can prevent invasion and metastasis by reducing hypoxia and HIF stabilization, indicating that modulation of the hypoxic response may enhance therapeutic efficacy of anti-angiogenic agents 75 . Metabolic reprogramming is a key adaptation to anti-angiogenic therapies, and several lines of evidence point to increased dependency on lipid metabolism during and after treatment with VEGF inhibitors 76, 77 . These preclinical studies indicate that understanding the dynamic response of hypoxia and HIF signalling to anti-angiogenic therapies may contribute to enhancing their efficacy.
Although prolonged VEGF blockade enhances tumour hypoxia and promotes tumour aggressiveness, recent studies indicate a therapeutic window during which tumour vasculature seems to normalize 78, 79 . Although vessel normalization is counterintuitive to the initial efforts of anti-angiogenic therapies, restored tumour oxygenation may enhance the delivery and efficacy of cytotoxic chemotherapies, as increased interstitial pressure and hypoxia are known to decrease drug delivery and efficacy 69 .
Cancer-associated fibroblasts
CAFs directly contribute to virtually every stage of tumorigenesis 80 . CAFs are a heterogeneous mix of myofibroblast-like cells that arise from various cell types, including normal fibroblasts, endothelial cells, adipocytes and bone-marrow-derived stromal cells [81] [82] [83] . Relative to normal fibroblasts, CAFs exhibit heightened metabolic activity and enhanced extracellular matrix (ECM) remodelling, properties that promote metabolic symbiosis and facilitate metastatic dissemination. CAFs secrete a variety of growth factors, cytokines and chemokines that stimulate cancer cell proliferation and recruit bone marrow-derived cells to the tumour site.
Hypoxic tumour cells secrete paracrine signalling factors, including transforming growth factor (TGF)-β, PDGF, chemokine (C-X-C motif) ligand 2 (CXCL2) and endothelin, that promote conversion of precursor cell types into CAFs, indicating the importance of hypoxia to CAF function in tumours 84 . Although hypoxia mediates CAF recruitment and activation through tumour cell intrinsic HIF signalling, the direct effects of hypoxia on CAFs remain elusive. Fibroblast-specific loss of HIF-1α induces vascular normalization, decreases hypoxia and enhances tumorigenesis in a mouse model of breast cancer, indicating that HIFsignalling in CAFs may inhibit tumorigenesis 85 . Indeed, hypoxia or loss of PHD2 leads to a decrease in CAF-induced ECM remodelling and diminished metastasis 86, 87 . These findings indicate the complex role of hypoxia and HIF signalling in CAF function. Below we highlight three major mechanisms through which CAFs modulate tumorigenesis and discuss how hypoxia influences these pathways.
Extracellular matrix remodelling.
The ECM is composed of fibrous proteins, including collagen and proteoglycans, that provide the structural fabric of tissues. During tumour growth, extensive ECM remodelling releases paracrine growth factors that stimulate tumour growth and enables tumour migration and metastasis. To facilitate ECM remodelling, CAFs express enzymes including collagen prolyl and lysyl hydroxylases and lysyl oxidases that catalyse crosslinking of collagens to elastin and other ECM molecules, resulting in increased matrix stiffness 88 . Hypoxia is an important stimulus of this process, driving increased expression of remodelling enzymes, including prolyl-4-hydroxylases and lysyl oxidases, leading to increased tumour stiffness and enhanced metastasis 84 .
Reprogrammed cellular metabolism. Compared with normal fibroblasts, CAFs exhibit increased glycolysis, which is critical for their ability to promote tumorigenesis, at least in part by activating HIF signalling 89 .
The metabolic by-products of CAF metabolism can be taken up by tumour cells to feed anabolic metabolism and tumour cell proliferation, suggesting that metabolic symbiosis is a key mechanism by which CAFs support tumour growth 90 . Gain-of-function studies in fibroblasts indicate that expression of HIF-1α, but not HIF-2α, regulates aerobic metabolism and tumour-promoting effects of CAFs 91 . In addition to exhibiting enhanced glucose uptake and glycolytic flux, cancer cells also take up significant amounts of lactate by expressing the lactate transporter MCT1 92, 93 . CAFs produce and secrete large amounts of lactate, which can be taken up by tumour cells to feed the tumour's requirement for central carbon metabolism 94 . Tumour cells alter ROS signalling in the microenvironment, which may promote HIF-dependent and -independent metabolic reprogramming in CAFs, thus potentiating metabolic symbiosis between these cell types 95 . These results indicate a dynamic interplay between the metabolism of CAFs and tumour cells, and suggest that targeting CAF metabolism could interfere with metabolic symbiosis in the tumour microenvironment and thus impair tumour growth.
Paracrine signalling. CAFs are an important source of signalling factors that act on tumour and stromal cells to potentiate paracrine signalling within the tumour microenvironment. CAFs exposed to hypoxia secrete stromal-cell-derived factor-1 (SDF-1, also known as CXCL12), which promotes tumour growth through paracrine mechanisms 96 . Hypoxia also upregulates expression of the SDF-1 receptor CXCR4 in numerous cell types, thus potentiating the paracrine signalling between CAFs and malignant cells 97 . In prostate cancer, androgen ablation therapy enhances tumour hypoxia, stimulating increased CXCL13 secretion from tumourresident myofibroblasts, leading to disease progression 98 . Indeed, several factors involved in the transformation of CAFs from precursor cells, including TGF-β, PDGF-B and basic fibroblast growth factor (bFGF), are directly or indirectly regulated by HIF, indicating the importance of hypoxia in regulating paracrine signalling in CAFs [99] [100] [101] Paracrine signalling by hypoxic CAFs also contributes to the immunosuppressive nature of the tumour microenvironment, by inducing secretion of arginase II (ArgII). ArgI and ArgII are important drivers of immune suppression in the tumour microenvironment because they promote conversion of L-arginine to ornithine, leading to T cell anergy and limited anti-tumour immune response 102 . In pancreatic cancer, CAFs localized to hypoxic tumour regions express high levels of ArgII, indicating an important role for hypoxia in CAF-mediated immunosuppression 103 .
Immune cells in the tumour microenvironment Tumour-infiltrating immune cells play an important role in disease progression, and anti-tumour immune therapies have been the subject of intense research for some time. Traditionally, these approaches have involved augmenting intrinsic anti-tumour immunity with cytokines such as IL-2, or tumour-antigen vaccines. However, the tumour microenvironment is functionally immunosuppressive, and intrinsic HIF signalling drives resistance to immune-mediated tumour cell lysis, limiting the efficacy of these therapies in all but a subset of patients 24, 104 . Consequently, a better understanding of how the microenvironment limits the effectiveness of immunotherapy could improve the efficacy of this treatment modality.
Tumour-infiltrating immune cells encompass a diverse array of cell types, including tumour-associated macrophages (TAMs), myeloidderived suppressor cells (MDSCs), T cells, neutrophils and others 3 . In most tumours, immune cells are recruited from the circulation by tumour-secreted cytokines and chemokines 105 . Hypoxia is known to directly or indirectly modulate the function of virtually all immune cell types, thereby facilitating tumour progression 106 . Indeed, myeloidspecific loss of PHD2 has been reported to impair tumour growth and metastasis, suggesting an important role for myeloid cell oxygen sensing in tumorigenesis 107 . Hypoxic regions in solid tumours offer distinct niches that fine tune the tumour-immune-system interface and enhance pro-tumorigenic phenotypes of tumour-infiltrating lymphocytes. Below, we discuss the role of hypoxia and HIF-signalling in innate and adaptive tumour immunity.
Cells of the innate immune system
Innate immune cells can potentiate the anti-tumour activity of tumourinfiltrating lymphocytes, leading to remarkable immune-mediated tumour regression in a subset of cancer patients. However, tumour microenvironmental factors, including hypoxia, limit the ability of the innate immune system to activate adaptive immunity, and instead subvert the function of the innate immune system to promote tumorigenesis.
Tumour-associated macrophages. Macrophage density correlates with poor prognosis in various cancer types, indicating an important role for macrophages in tumour progression 108, 109 . Hypoxia in the tumour microenvironment is a potent stimulus for macrophage recruitment through the induction of chemoattractant secretion by tumour cells (Fig. 3) . Sema3A is such a factor, and attracts macrophages through neuropilin 1 (Nrp1)-plexin signalling 110 . Hypoxia also induces secretion of chemokines, such as endothelial-monocyte-activating peptide II (EMAP II), endothelin-1 and endothelin-2 (ET-1 and ET-2) that recruit macrophages to the tumour 111, 112 . In ovarian cancer, hypoxia drives macrophage recruitment by stimulating the production of pro-inflammatory leukotrienes, a process that can be reversed by pharmacologic targeting of leukotriene production 113 . Macrophage activation includes the classically activated M1 phenotype, which is characterized by iNOS expression, pro-inflammatory cytokine production and tumour suppression. In contrast, alternatively activated (M2) macrophages express arginase 1 (Arg1), promote angiogenesis, secrete anti-inflammatory glucocorticoids and effectively dampen the anti-tumour immune response. Consequently, M1 macrophages oppose whereas M2 macrophages promote tumour progression and metastasis 114 . Macrophage polarization in the tumour microenvironment is heterogeneous and dynamic, and hypoxia plays an important role in this process (Fig. 4a) . Blockade of Sema3A-stimulated macrophage recruitment + T reg cells with reports suggesting that HIF either induces or inhibits the formation of both cell types. In contrast, overwhelming evidence indicates that hypoxia stimulates the secretion of a number of cytokines and chemoattractants from cancer cells and tumourassociated macrophages, including CCL28, CCL22 and IL-10, that recruit T reg cells from the circulation. On a cell intrinsic basis, hypoxia stimulates T reg cell production of CD73, thereby increasing adenosine levels in the tumour microenvironment, resulting in inhibition of effector T cells. Hypoxia also stimulates production of other immune suppressive molecules, including galectin-1, transforming growth factor (TGF-β) and IL-10. IFN-γ, interferon-γ; GM-CSF, granulocyte macrophage colony-stimulating factor; A2aR, A 2A adenosine receptor.
to hypoxic tumour regions skews macrophages towards the M1 phenotype, indicating that therapeutic blockade of Sema3A may promote anti-tumour activity of TAMs 110 . Preclinical studies further indicate that vascular normalization after low-dose irradiation decreases tumour hypoxia and promotes M1 polarization of TAMs, an effect that may be exploited to enhance anti-tumour immunity 115 . Hypoxia can directly impact macrophage polarization by inducing M2-like gene expression in TAMs
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. HIF-1α and HIF-2 seem to play opposing roles in macrophage polarization, with HIF-2α specifically induced in response to T H 2 cytokines in macrophages 117 . HIF-1α and HIF-2α are nevertheless essential for macrophage function, as loss of HIF-1α results in defective macrophage maturation and function 118 . Furthermore, genetically engineered mouse models indicate that expression of HIF-1α and HIF-2α are essential for macrophage infiltration and immune suppression within tumours, and loss of either isoform in macrophages diminishes tumour growth 119, 120 . Elevated lactate levels in tumours promote M2 polarization in a HIF-1α-dependent manner, indicating that hypoxic metabolism by tumour cells also impacts macrophage polarization 121 . These findings indicate that a combination of microenvironmental hypoxia and metabolic symbiosis between tumour cells and macrophages skew their polarization and shape the anti-tumour immune response 122, 123 . In addition to mediating immunosuppression, M2 macrophages are important drivers of angiogenesis, indicating an intricate cross-talk between hypoxic tumour cells, macrophages and endothelial cells that dictates oxygen availability in the tumour, cellular metabolism and the anti-tumour immune response 124 . Thus, TAMs have a significant and direct impact on hypoxia in the tumour microenvironment, creating a feedback loop between oxygen availability and recruitment and polarization of TAMs.
Myeloid-derived suppressor cells. MDSCs are bone-marrow-derived cells that suppress the anti-tumour immune response. MDSCs exposed to hypoxia induce HIF signalling and upregulate HIF targets that enhance MDSC function 125 . Hypoxia enhances MDSC suppressor function through a mechanism that is partially dependent on the HIFregulated microRNA miR-210 and increased expression of ArgI 125, 126 . Tumour hypoxia also influences seeding of MDSCs in the pre-metastatic niche by stimulating increased secretion of lysyl oxidase [127] [128] [129] . This process drives ECM remodelling in the metastatic niche and suppresses natural killer anti-tumour immune responses 127 . The enhanced MDSC suppressor function in hypoxia indicates an additional mechanism by which the hypoxic microenvironment suppresses anti-tumour immunity.
Tumour-associated neutrophils. Tumour-associated neutrophils (TANs) can have both pro-and anti-tumorigenic properties 130 . Hypoxia in the tumour microenvironment promotes neutrophil recruitment by changing the adherence properties of endothelial cells to neutrophils 131 . In a preclinical model of uterine carcinoma, hypoxia-mediated neutrophil recruitment impeded tumour growth, indicating a tumour suppressive role for neutrophils in this cancer type 132 . Hypoxia prolongs neutrophil survival, and HIF-dependent increases in glycolytic metabolism are important for neutrophil function in hypoxia 118, 133 . Similar to macrophages, neutrophil function can be classified into N1 and N2 polarization, with N2 neutrophils displaying tumour-promoting properties analogous to the role of M2 macrophages in tumour progression 134 . TGF-β in the tumour microenvironment promotes N2 neutrophil polarization, thereby enhancing their tumour-promoting function 135 . Despite the association between HIF-α signalling and TGF-β, whether hypoxia directly modulates neutrophil polarization remains unclear.
Cells of the adaptive immune system
Cells of the adaptive immune system, such as tumour-infiltrating lymphocytes, have the potential to effectively eliminate tumour cells from the body by recognizing tumour-associated antigens. However, the hypoxic tumour microenvironment limits their anti-tumour activity by promoting immune checkpoint activation, limiting access to key nutrients and recruiting a variety of immunosuppressive cell types to the tumour site, thereby reducing the effectiveness of the anti-tumour immune response. 137, 138 (Fig. 4b) . Hypoxia also stimulates production of extracellular adenosine by T reg cells, which inhibits effector T cell function through activation of cAMP signalling 139, 140 . Surprisingly, although hypoxia promotes critical T reg functions, constitutive activation of HIF-1α, achieved through T reg cell-specific VHL deletion, disrupts T reg cell function and drives IFN-γ-mediated tissue inflammation, indicating that physiologically appropriate levels of HIF signalling are important for T reg cell differentiation 141 . Whereas T reg cells are functionally immunosuppressive, T helper 17 (T H 17) cells are pro-inflammatory CD4 + T cells that play a complex and controversial role in anti-tumour immunity 142 . Hypoxia promotes the differentiation of naïve CD4 + T cells into T reg or T H 17 cells by modulating expression of FOXP3 and RORγt (RAR-related orpha receptor γ), essential transcription factors for these respective cell types 23, 143, 144 (Fig. 4b) . Induction of T H 17 cell development is accompanied by increased glycolysis driven by mTOR-HIF-1α signalling 145 . In contrast, T reg cells rely primarily on β-oxidation for their metabolic function. More work is needed to understand the complex and seemingly contradictory effects of HIF signalling on T H 17 and T reg cell development, including whether different mechanisms of HIF activation (hypoxia versus TCR signalling) result in different T cell fate decisions.
Promising results from clinical trials have dramatically increased interest in targeting immune checkpoints in cancer therapy. So far, most attention has focused on targeting the receptors, programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and their ligands PD-L1 and PDL-2 and CD80 and CD86, respectively, but the number of targets is likely to increase as knowledge of immune checkpoint regulation expands 146 . Recent studies revealed direct regulation of PD-L1 in MDSCs and tumour cells by HIF-1α, indicating that hypoxia transcriptionally modulates immune checkpoints 147 . Similarly, in vitro studies in human and canine cell lines indicate that PD-L1 is induced in a HIF-1α-dependent manner on exposure to hypoxia, and that this induction inhibits T-cellmediated lysis 148 .
Conclusions
Unlike genetic aberrations, which directly modulate tumour cell function, microenvironmental factors such as hypoxia influence both tumour and stromal cells. Hypoxia promotes genomic instability in cancer cells, and also recruits vascular endothelial cells and regulates pericyte function to promote angiogenesis, thereby increasing nutrient and oxygen supply and facilitating metastatic dissemination. In CAFs, hypoxia promotes symbiotic metabolism, ECM remodelling and secretion of paracrine factors that support primary tumour growth and metastasis. Hypoxia also drives recruitment of various immune cells and promotes an immunosuppressive microenvironment to limit anti-tumour immunity. On a global level, low oxygen levels trigger HIF-dependent and -independent adaptive responses in both tumour and stromal cells that increase tumour aggressiveness and metastasis. Tumour hypoxia fluctuates during tumour growth and in response to cytotoxic and targeted therapies, with profound impacts on disease progression and therapeutic efficacy. As our understanding of the hypoxic response in stromal and tumour cells increases, developing cancer therapies against hypoxia response pathways is emerging as an attractive option. Delivery of such therapies could be timed to coincide with the increased hypoxia observed with VEGF blockade, to prevent the hypoxiaassociated increased aggressiveness on VEGF inhibition. Another potential therapeutic approach would be to directly target HIF transcriptional activity, for example by exploiting potential small-molecule binding pockets revealed by the elucidation of the ARNT-bound HIF-1α and HIF-2α crystal structures 149, 150 . A better understanding of the effects of hypoxia and HIF-mediated responses in CAFs and immune cells, including macrophages, T cells and neutrophils, could also allow their therapeutic manipulation to stimulate anti-tumour immune responses. Likewise, elucidating the role of HIF signalling in controlling immune checkpoint signalling components could be useful in cancer immunotherapy.
Given their potential to inhibit tumour-promoting pathways in both malignant and stromal cells, the development of therapeutic approaches targeting HIF signalling directly or by inhibiting downstream effector pathways holds great promise for cancer treatment.
